IMNM FY 2022 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$37M

EPS (Diluted)

$-3.09

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$24M

Total Liabilities

$7M

Stockholders' Equity

$17M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$25M	-46.4%
Net Income	-$37M	-$25M	-49.3%